 |  | 

Cancer-Fighting Drug May Work In Prevention And Treatment
PHILADELPHIA
The ABCs of fighting cancer these days include
two big words that describe exciting basic concepts. One is anti-angiogenesis,
a strategy to stop or prevent the growth of blood vessels needed
to nourish a tumor and allow it to spread.
Another approach is
chemoprevention-using medication to halt, delay or reverse the
development of cancer.
According to new prevention research by Fox Chase Cancer Center
cell biologist Margie Clapper, Ph.D., of Harleysville, Pa., and
colleagues at Cephalon Inc. in West Chester, Pa., the drug Oltipraz
holds the potential to achieve both goals.
A report on the ongoing
studies appears in the January 2002 issue of Clinical Cancer
Research. Co-authors include Dr. Clapper and Bruce Ruggeri, Ph.D.,
of Cephalon's Division of Oncology.
Clapper has been studying Oltipraz for more than a decade, concentrating
on its ability to raise blood levels of protective "detoxification"
enzymes that help ward off cancer. These enzymes resemble antioxidant
compounds in broccoli, cabbage and similar vegetables.
In early clinical studies, Clapper worked with Fox Chase medical
oncologist Christine Szarka, M.D., to see how well Oltipraz increased
protective enzymes among people at high risk of colon cancer.
For comparison, some trial participants took dried broccoli tablets
instead of the drug. Oltipraz surpassed the dietary approach
by a significant measure with few or no side effects. A later
study used Oltipraz for people at risk of lung cancer.
Most recently, with support from the Cancer Research Foundation
of America, Clapper has focused on individuals with ulcerative
colitis, which increases the risk of colon or rectal cancer by
10 times. In studies with laboratory mice, Oltipraz has proved
to inhibit colitis-associated colon cancer. This research will
form a basis for designing the first trial of a preventive treatment
for people with this disease.
The drug's ability to boost protective enzymes and decrease DNA
damage from cancer-causing agents was thought to explain its
success in halting the development and spread of a variety of
tumors in mice and rats.
But in evaluating this laboratory work,
Clapper says, "we've seen tumor growth halted without an elevation
of detoxification enzymes."
[01/07/2002; ScienceDaily]
|
Remember we are NOT Doctors and have NO medical training.
This site is like an Encylopedia - there are many pages, many links on many topics.
Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM. |
|